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In this issue of Chemistry & Biology, Mantelingu and colleagues present the development of the
garcinol derivative LTK-14, which is a specific and nontoxic inhibitor of histone acetyltransferase
p300-HAT [1]. Interestingly, it blocks histone acetylation of HIV-infected cells resulting in inhibition
of the multiplication of HIV in these cells.In 1963 Jack H. Rubinstein and
Hooshang Taybi described a child-
hood disease characterized by typical
facial abnormalities, broad thumbs,
broad big toes, growth and mental
retardation, and an increased risk of
neoplasia [2]. The molecular basis of
the Rubinstein-Taybi Syndrome was
later discovered to be disruption of
one copy of the human CREB binding
protein (CBP or CREBBP) gene that
encodes the histone acetyltransferase
CBP [3]. In addition to CBP, all mam-
mals have a closely related factor,
p300. In general, CBP and p300 are
distinct but closely related proteins,
which share extensive homology and
perform not only overlapping but also
unique functions [4]. Both CBP and
p300 are able to acetylate specific
lysine residues of histones H2A, H2B,
H3, and H4, as well as nonhistone
proteins, like p53. Through their
acetyltransferase activity, as well as
through their ability to interact with
a large number of nuclear proteins,
they are involved in a plethora of
biological processes like transcription,
differentiation, transformation, apo-
ptosis, and embryonic development.
For example, they participate in vari-
ous tumor-suppressor pathways (i.e.,
wnt, p53) and they are also necessary
for the actions of many cellular and
viral oncogenes (i.e., c-jun, c-fos,
c-myb, v-myb) [5]. Several viruses en-
code proteins such as the adenoviral
E1A, the HTLV-1 Tax, and the simian
virus 40 large T protein to specifically
target CBP/p300 and to cause a loss
of cell growth and enhance DNA syn-
thesis. There is also evidence that the
demand for CBP/p300 is greater than
the supply, and the competition for
these enzymes plays an importantrole in cell growth regulation [6]. In
some instances, CBP and p300 can
contribute to opposing cellular pro-
cesses [5].
In eukaryotic cells, DNA is organized
in a highly complex structure, chroma-
tin, by both histone and nonhistone
proteins. Acetylation of specific lysine
residues in these proteins is a well-
known posttranslational modification,
which regulates chromatin structure
and assembly, and trancription of
many genes. Two classes of enzymes,
histone acetyltransferases (HATs) and
histone deacetylases (HDACs), keep
the balance of specific acetylation
levels for proper cellular function. Dys-
regulation of either of these enzymes
may lead to different diseases includ-
ing cancer, diabetes, and AIDS. HATs
are a diverse set of enzymes that are
grouped into different family classes
based on their catalytic domains.
These include the GNAT, MYST, and
the p300/CBP families [7]. In order to
get insights into these CBP/p300-
mediated biological effects cell-
permeable small molecules acting as
specific CBP/p300 inhibitors are nec-
essary. These molecules can be also
regarded as valuable tools in the area
of epigenetics, as well as anticancer
and antiviral drug candidates.
In this issue of Chemistry & Biology,
Mantelingu and colleagues report on
the development of the garcinol deriv-
ative LTK-14 (Figure 1), a specific
inhibitor of p300-HAT. Contrary to the
parent compound garcinol, LTK-14
was found to be nontoxic to T cells.
Interestingly it inhibits histone acetyla-
tion of HIV infected cells resulting in
inhibition of the multiplication of HIV
in these cells. The SAR studies per-
formed by the authors showed thatChemistry & Biology 14, June 2007 ª2the reason for the low toxicity of LTK-
14 is the introduction of a methyl group
at the aromatic moiety of garcinol. It
is known that 1,2-dihydroxybenzene
derivatives (catechols) are metabo-
lized to afford the corresponding
highly reactive ortho-quinones which
display cell toxicity due to their ability
to react with DNA affording depuri-
nated adducts [8]. By alkylation of
one of the two phenolic groups in
garcinol an oxidation to ortho-
quinones is no longer possible result-
ing in the observed lower toxicity.
Furthermore, by introduction of a cycli-
zation at the southeast part of garcinol,
specificity was established: LTK-14 is
an inhibitor of p300 and is inactive
against PCAF, a member of the
GNAT family.
The observation of the cytostatic
and anti-HIV activity of phloglucinol
derivatives is not new. Previously, a
series of polyprenylated benzophe-
nones (i.e., compounds 2 and 3, Fig-
ure 1) from Garcinia, Clusia, and Sym-
phonia species from the large plant
family Guttiferae were reported to
exhibit cancer chemopreventing and
anti-HIV activities [9, 10].
Recently, Balasubramanyam and col-
leagues were able to shed light on the
mechanism of the action of these natu-
rally occurring compounds [11]. They
identified garcinol to be a histone acetyl-
transferase inhibitor which represses
chromatin transcription. They reported
that garcinol inhibits histone acetyltrans-
ferases p300 with an IC50 =7 mM and
PCAF with an IC50 =5 mM.
In light of this evidence, Mantelingu
and colleagues developed derivative
LTK-14 for investigation of the role of
CBP/p300 protein in global gene
expression [1]. Microarray analysis007 Elsevier Ltd All rights reserved 605
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ated acetylation by LTK-14 downregu-
lates 118 genes and upregulates
6 genes. Furthermore, they showed
that derivative LTK-14 inhibited HIV
replication in SupT1 cells. How can
this be explained? Upon infection of
susceptible cells, the RNA genome
of the human immunodeficiency virus
type 1 (HIV-1) is reverse transcribed
into double-stranded DNA by the
enzyme HIV-1 reverse transcriptase
(HIV-1 RT), which is then inserted and
integrated into the host genome by
the HIV-1 integrase (HIV-1 IN). It has
been showed that p300 acetylates
three lysines in the carboxy terminus
of IN, which is important for DNA bind-
ing. This modification increases IN
affinity to DNA and also its enzymatic
activity. After integration, the viral
long term repeat (LTR) promoter is
almost silent when integrated into the
cellular genome. Histone acetylation
at the LTR promoter plays an impor-
tant role in the activation of HIV tran-
scription. Activation of LTR requires
the virally encoded transactivator of
transcription (Tat), which induces the
association of p300 and the CBP with
the LTR promoter [12].
LTK-14 will be a valuable tool to
study histone and nonhistone protein
acetylation, as well as an experimental
anti-HIV agent. However several im-
portant and critical caveats remain.
How specific are these garcinol deriv-
atives? In the light of the very recent
discovery that similar phloglucinols
like Hyperforin and Aristoforin (Fig-606 Chemistry & Biology 14, June 2007 ªure 1) are potent inhibitors of Sirtuins
SIRT1 and SIRT2 [13], it is necessary
to investigate if LTK-14 has similar
properties. Furthermore, due to the
fact that CBP/p300 is involved in tumor
suppression (for example inhibition of
wnt pathway) and the observation
that patients with Rubinstein-Taybi
Syndrome have a higher incidence of
hematologic malignancies it is rather
unlikely that LTK-14 will find applica-
tion in cancer therapy. A possible
neurotoxicity of CBP/p300 inhibitors
should be also taken into consider-
ation. It is known that loss of function
of CBP protein underlies several neu-
rological disorders [14]. Finally, in a
recent study, the mechanism of hepa-
toxicity of the antihypertensive drug
todralazine was investigated. After
long-term administration this drug is
known to cause liver failure [15]. It
was shown that histone acetylation
was significantly impaired in patients
treated with this drug. In vitro experi-
ments showed that todralazine and
analogs inhibit histone acetylation in
a dose-dependent manner.
Despite these facts it is important to
emphasize that LTK-14 is an interest-
ing tool in the area of epigenetics [16]
and may also find application in exper-
imental antiviral therapy and in the
study of processes like cancer, age-
ing, neurodegenerative diseases, obe-
sity, and diabetes. In the light of other
recent discoveries that similar natu-
rally occurring phloroglucinols are
able to modulate the acetylation status
of histone and nonhistone proteins2007 Elsevier Ltd All rights reserved[13], it will be interesting to investigate
the ability of other members of the
phloroglucinol class of natural prod-
ucts to influence the activity of
histone-modifying enzymes [17].
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